Nanopublication

< Home

ID

http://purl.org/np/RAH-8nVPXuLdCWTXbyVdxkCUyTfbrkvlBRi50_OKcfdvM

Formats

.trig | .trig.txt | .jelly | .jelly.txt

Content

@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix ns1: <https://w3id.org/np/o/ntemplate/> .
@prefix this: <http://purl.org/np/RAH-8nVPXuLdCWTXbyVdxkCUyTfbrkvlBRi50_OKcfdvM> .
@prefix sub: <http://purl.org/np/RAH-8nVPXuLdCWTXbyVdxkCUyTfbrkvlBRi50_OKcfdvM#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: a np:Nanopublication;
    np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_1686> biolink:category biolink:Disease .
  
  sub:association a rdf:Statement;
    rdf:object <http://purl.obolibrary.org/obo/DOID_1686>;
    rdf:predicate biolink:treats;
    rdf:subject <https://identifiers.org/drugbank:DB01173>;
    rdfs:label "Orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis. Orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.";
    biolink:provided_by <https://w3id.org/um/NeuroDKG>;
    biolink:relation schema:MedicalContraindication .
  
  <https://identifiers.org/drugbank:DB01173> biolink:category biolink:Drug .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "On7YSpaFsTsY4i1/nawDQAYXt/oiwbNk0NI24hf1uQcWE2ATujgLg+EuS3EeNxSgIBBR5xyJTAAOCX5rie1P1sh5BE/h1PmIc/jhtNNB99vSzDY9ZcVFo9cHKm/TTuhI5vZH79/DDLs3nk6opW6OFs2liYiu4yfMNbSzXyZP2Js=";
    npx:hasSignatureTarget this: .
  
  this: dct:created "2021-08-25T14:33:31.025+02:00"^^xsd:dateTime;
    dct:creator orcid:0000-0002-1468-3557;
    ns1:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    ns1:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    ns1:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .
}